【摘要】 目的探讨环磷酰胺(CTX)联合多西紫杉醇(Docetaxel)治疗转移性乳腺癌的临床疗效,为临床治疗转移性乳腺癌提供数据支持。方法回顾性分析2008年8月～2011年8月我院采用环磷酰胺联合多西紫杉醇治疗的112例转移性乳腺癌患者的临床资料,并以同期采用长春瑞滨(NVB)联合吡柔吡星(THB)治疗的112例患者为对照组,比较2组患者治疗效果和不良反应发生率。结果观察组总缓解率为52.68%,对照组为42.86%,组间比较差异具有统计学意义(χ2=9.457,P<0.05)。观察组患者不良反应发生率为25.00%,对照组为25.89%,观察组低于对照组,但是组间比较差异无统计学意义(χ2=2.042,P>0.05)。结论环磷酰胺联合多西紫杉醇治疗转移性乳腺癌疗效确切,值得临床推广应用。更多还原

【Abstract】 Objective To Discusis the effect of cyclophosphamide (CTX) joint Docetaxel (Docetaxel) metastatic breast cancer treatment of the clinical curative, for clinical treatment metastatic breast cancer provide data support. Methods Retrospective analysis from August 2008 to August 2011 by cyclophosphamide our joint, docetaxel treatment of 112 patients with metastatic breast cancer patients’ clinical material, and the same period to the shore of the red changchun (NVB) joint imidacloprid soft imidacloprid star (THB) treatment of 112 patients as control group, compared with two groups of patients treatment effect and adverse reaction rate. Results The observation group total remission rate was 52.68%, to 42.86% in the placebo group, the group is a statistically significant differences between (the chi-square=9.457, P<0.05). The observation group patients adverse reaction rate of 25.00%, to 25.89% in the placebo group, the observation group lower than those of the control group, but comparing between groups was statistically significant (the chi-square=2.042, P>0.05). Conclusion Cyclophosphamide joint, docetaxel treatments for metastatic breast cancer symptoms, and worth of clinic application.更多还原